Fig. 1

A significant difference in mean systolic blood pressure (a) and diastolic blood pressure (b) is observed between Canagliflozin and placebo groups. In Canagliflozin group both decreased from visit 1 to 2 and increased by visit 3. Whereas in placebo group both increased from visit 1 to 2 and decreased by visit 3. c HbA1c went down substantially in Canagliflozin group whereas it increased in Placebo group. The sharp decrease in HbA1c is seen in visit 1to visit 2 (p = 0.0919) and is stabilized from visit 2 to visit 3 in Canagliflozin group. d Glucose levels also followed the same trend as HbA1c in Canagliflozin group by sharp decrease from visit 1 to 2 and then stabilized till visit 3. Whereas, in placebo group glucose levels increased from visit 1 to 3. e A significant rise in adiponectin levels is noted in Canagliflozin group where as a sharp decrease is observed in placebo group from visit 2 to 3. f Inflammatory marker serum IL6 levels decreased. The difference was significant from visit 2 to 3 (p = 0.0259) in Canagliflozin group as compared to placebo group